We are recruiting two exciting #Postdoctoral roles: 🧪 Work with @clausjorgensen.bsky.social on targeting the tumour #microenvironment in #PancreaticCancer 🥼 Join @drwilliamhill.bsky.social to study air pollution & #LungCancer Full details of both positions at: www.cruk.manchester.ac.uk/careers/

Thrilled to announce I'm moving to Manchester to lead the Cancer Origins group! If you're interested in how mutations and exposures drive tumourigenesis — come join the adventure

Our lab is hiring! This is for a postdoctoral position @ucl.ac.uk in Respiratory Medicine. Please check out the link for more details: www.ucl.ac.uk/work-at-ucl/...

🧬 Glasgow researcher Dr Alexander Raven has been awarded a prestigious UKRI Future Leaders Fellowship to advance understanding of how liver cancer develops, with the aim of improving detection and treatment 📍 University of Glasgow 👇 Learn more glasgowcityofscienceandinnovation.com/glasgow-canc...

Please apply to our tenure-track faculty position at @stanford-chemh.bsky.social! We are searching for a new colleague working at the interface between computation and molecular sciences. See post below and pls forward widely! chemh.stanford.edu/opportunitie...

My main PhD project is now up on bioRxiv! If you’re interested in somatic evolution or machine learning for simulation-based inference, read on…
 doi.org/10.1101/2025... [1/15]

I am thrilled to have received a UKRI Future Leaders Fellowship! This award will enable my laboratory to uncover how our body's natural antiviral defences, including APOBEC3 enzymes, contribute to the earliest stages of lung cancer. 🧪 www.ukri.org/news/ukri-an...

A study led by @jeffreytownsend.bsky.social reveals #tobacco alters lung #adenocarcinoma evolution: smokers’ tumors favor KRAS/KEAP1/STK11, never-smokers’ favor EGFR/PIK3CA—revealing distinct treatment vulnerabilities. biorxiv.org/content/10.1... @toomuchvitamink.bsky.social

🚨 PhD Position available in our lab 🚨 exploring the power of blood immune multi-omics to detect lung cancer years prior to clinical diagnosis in a unique cohort of >10,000 CT screened individuals. ✅ Wet & dry lab ✅ September 2025 enrolment ✅ UK tuition fees only www.ucl.ac.uk/medical-scie...

A study in Nature shows that respiratory viruses trigger metastatic breast cancer cells to proliferate in lungs in mouse models of breast cancer. These findings are supported by human observational data. go.nature.com/4l7NZ8l #medsky 🧪

Beautiful work!

Exciting! 🧪

I am excited to announce that my laboratory @ucl.ac.uk is now open! We are hiring so please contact us if you are interested. www.caswelllaboratory.com

Our paper on the effect of herpes zoster vaccination on dementia is now out in Nature! 🎉 Huge thanks to Felix Michalik, Seunghun Chung, @pascalge.bsky.social and especially Min Xie (@minxiesci.bsky.social) & Simon Heß (@hesss.org) making the analysis so much fun! www.nature.com/articles/s41...

Personalized therapeutic strategies that target APOBEC 🧪 offer promise for the enhancement of TKI treatment efficacy by delaying the evolution of drug resistance in lung cancer. www.sciencedirect.com/science/arti...

Our data-driven analysis indicates that inhibition of APOBEC activity would substantially extend therapeutic efficacy 🧪, with the degree of benefit varying based on patient-specific APOBEC mutagenesis levels. www.sciencedirect.com/science/arti...

By analyzing tumor sequence data to infer gene-specific and patient-specific mutation rates, we used (for the first time) some straightforward mathematics of mutation rates to project the delay of resistance obtained by suppression of APOBEC mutation 🧪. www.sciencedirect.com/science/arti...

@alkpositiveuk.bsky.social—ALK resistance mutations show greater APOBEC attribution than e.g. EGFR mutations. Therefore, patients with ALK+ tumors would benefit more from therapies suppressing APOBEC activity 🧪. www.sciencedirect.com/science/arti...

We estimated the contribution of APOBEC to mutational signatures in the twenty-one NSCLC patients that featured detailed clinical records of TKI treatment 🧪 and tissue sampling during or after treatment or at autopsy. www.sciencedirect.com/science/arti...

Thanks for mentioning our article @jeffreytownsend.bsky.social. Your paper projecting how APOBEC inhibition could improve outcomes in patients with non-small cell lung cancer is fascinating!

APOBEC drives genetic variation in lung tumors, especially in response to tyrosine kinase inhibitor therapy 🧪. Inhibition of APOBEC during use of tyrosine kinase inhibitors could improve outcomes. In a paper just out in Lung Cancer, we show how much. www.sciencedirect.com/science/arti...

My NIH study section that was to meet tomorrow was one of those canceled. This represents many months of work by the applicants and by the NIH staff and reviewers. Devastating is the correct word.

Our study on the effectiveness of the COVID-19 vaccines in preventing disease in pregnant women and their infants is now published in BMJ Medicine. https://bmjmedicine.bmj.com/content/3/1/e000696

New Lab Preprint!🥳 Using CRISPR-Translate, a genome-wide CRISPR-Cas9 knockout screening method developed by the lab exploiting translation levels as a readout, we reveal that PACT is an inhibitor of PKR and not an activator during RNA viral infections. www.biorxiv.org/content/10.1...

Please check out our publication with @DrPhilippeGui, @charlesswanton.bsky.social, @BivonaLabUCSF, @Downwardlab, and @HarrisLabUTHSA! www.nature.com/articles/s41...

Thank you so much @CRUKCOLcentre for the funding and for featuring me in your newsletter. I am thrilled! www.colcc.ac.uk/spotlight-on...

🧬 I'm happy to announce that our latest study, "ATR safeguards replication forks against APOBEC3B-induced toxic PARP1 trapping," is now available on bioRxiv! 🧬 Check it out here: biorxiv.org/content/10.1... @buissonlab.bsky.social

New Lab Preprint! We show that ATR inhibition results in hyperactivation of PARP1 at replication forks, driven by APOBEC3B, UNG2, and APE1 reaction cascade targeting unprotected single-stranded DNA at the forks. www.biorxiv.org/content/10.1...

Anyone interested in APOBECs and/or DNA editing should consider attending The 6th International Conference on Base Editing, Prime Editing & Related Enzymes. "Deaminet" runs January 22-24, 2025 at Hotel Zoso in Palm Springs, California. It's a great meeting! uthscsa.edu/medicine/edu...